Skip to main navigation Skip to search Skip to main content

Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS i and II

  • Scott R. Evans
  • , Andrea M. Hujer
  • , Hongyu Jiang
  • , Kristine M. Hujer
  • , Thomas Hall
  • , Christine Marzan
  • , Michael R. Jacobs
  • , Rangarajan Sampath
  • , David J. Ecker
  • , Claudia Manca
  • , Kalyan Chavda
  • , Pan Zhang
  • , Helen Fernandez
  • , Liang Chen
  • , Jose R. Mediavilla
  • , Carol B. Hill
  • , Federico Perez
  • , Angela M. Caliendo
  • , Vance G. Fowler
  • , Henry F. Chambers
  • Barry N. Kreiswirth, Robert A. Bonomo
  • Harvard University
  • Case Western Reserve University
  • Louis Stokes Cleveland Department of Veterans Affairs Medical Center
  • Abbott Laboratories
  • Public Health Research Institute, New York
  • Cornell University
  • Duke University
  • Brown University
  • San Francisco Department of Public Health

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

Background. Rapid molecular diagnostic (RMD) platforms may lead to better antibiotic use. Our objective was to develop analytical strategies to enhance the interpretation of RMDs for clinicians. Methods. We compared the performance characteristics of 4 RMD platforms for detecting resistance against β-lactams in 72 highly resistant isolates of Escherichia coli and Klebsiella pneumoniae (PRIMERS I). Subsequently, 2 platforms were used in a blinded study in which a heterogeneous collection of 196 isolates of E. coli and K. pneumoniae (PRIMERS II) were examined. We evaluated the genotypic results as predictors of resistance or susceptibility against β-lactam antibiotics. We designed analytical strategies and graphical representations of platform performance, including discrimination summary plots and susceptibility and resistance predictive values, that are readily interpretable by practitioners to inform decision-making. Results. In PRIMERS I, the 4 RMD platforms detected β-lactamase (bla) genes and identified susceptibility or resistance in >95% of cases. In PRIMERS II, the 2 platforms identified susceptibility against extended-spectrum cephalosporins and carbapenems in >90% of cases; however, against piperacillin/tazobactam, susceptibility was identified in <80% of cases. Applying the analytical strategies to a population with 15% prevalence of ceftazidime-resistance and 5% imipenem-resistance, RMD platforms predicted susceptibility in >95% of cases, while prediction of resistance was 69%-73% for ceftazidime and 41%-50% for imipenem. Conclusions. RMD platforms can help inform empiric β-lactam therapy in cases where bla genes are not detected and the prevalence of resistance is known. Our analysis is a first step in bridging the gap between RMDs and empiric treatment decisions.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalClinical Infectious Diseases
Volume62
Issue number2
DOIs
StatePublished - 15 Jan 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • -lactams
  • empiric therapy
  • molecular diagnostics
  • β

Fingerprint

Dive into the research topics of 'Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS i and II'. Together they form a unique fingerprint.

Cite this